Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657637 | 0.82 | KHK (0.54) | VCAM1CYP2C9CYP1A2CYP2C19GRIA1 | |
| SCHEMBL1313328 | 0.82 | GRIA1 (0.46) | VCAM1CYP2C9CYP1A2CYP2C19GRIA1 | |
| SCHEMBL20265347 | 0.77 | TSHR (0.42) | VCAM1POLBTDP1ALDH1A1CYP3A4 | |
| SCHEMBL14683926 | 0.77 | CYP1A2 (0.44) | CYP1A2NPSR1MAPTPOLBHPGD | |
| SCHEMBL30515102 | 0.77 | CYP1A2 (0.44) | CYP1A2NPSR1MAPTPOLBHPGD | |
| SCHEMBL33526375 | 0.76 | NPSR1 (0.59) | CYP2C9CYP1A2CYP2C19NPSR1POLB | |
| SCHEMBL1314227 | 0.76 | GLA (0.43) | CYP2C9GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL1625612 | 0.75 | VCAM1 (0.51) | VCAM1CYP2C9CYP1A2GRIA1GRIA2 | |
| SCHEMBL1344104 | 0.75 | VCAM1 (0.51) | VCAM1CYP2C9CYP1A2CYP2C19GRIA1 | |
| SCHEMBL20303775 | 0.74 | NPSR1 (0.57) | CYP2C9CYP1A2CYP2C19NPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-9096525-B2 | Iminipyridine derivatives and their uses as microbiocides | SYNGENTA CROP PROTECTION, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096525-B2 | Iminipyridine derivatives and their uses as microbiocides | SYNGENTA CROP PROTECTION, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2375899-B1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES | ARRAY BIOPHARMA INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2375899-B1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES | ARRAY BIOPHARMA INC (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2015004481-A1 | IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015004481-A1 | IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014207508-A1 | PYRIDYL COMPOUND SUITABLE FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2014-12-31 | — | — | WO | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2125734-A2 | NOVEL MICROBIOCIDES | Syngeta Participations AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-2024356-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008101682-A2 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101682-A2 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | CD14, MYADM, MPO | VCAM1 439/4885CYP2C9 168/4885CYP1A2 194/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | VCAM1 2532/4885CYP2C9 1804/4885CYP1A2 2194/4885 |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | CETP, LCAT, CES1 | VCAM1 2876/4885CYP2C9 1006/4885CYP1A2 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.